论文部分内容阅读
目的探讨抗病毒治疗丙型肝炎肝硬化代偿期患者的临床疗效。方法收集我院2012年6月至2014年6月丙型肝炎肝硬化代偿期146例患者资料,将患者按照随机数表法分为两组,各73例,A1组患者给予聚乙二醇干扰素a-2a+利巴韦林治疗,A2组患者给予常规保肝治疗。比较两组患者治疗12、24周后肝功能指标。结果两组患者治疗12周后,TBIL、ALT、AST以及HCV-RNA水平与治疗前比较,差异均无统计学意义(均P>0.05);治疗24周后,A1组患者TBIL、ALT、AST以及HCV-RNA水平明显优于A2组,差异均有统计学意义(均P<0.05)。结论聚乙二醇干扰素a-2a+利巴韦林治疗丙型肝炎肝硬化代偿期患者,针对病毒复制可表现出明显的抑制作用,患者的肝脏功能可获得明显改善,效果明显。
Objective To investigate the clinical efficacy of antiviral therapy in patients with decompensated hepatitis C due to cirrhosis. Methods The data of 146 patients with decompensated hepatitis C cirrhosis from June 2012 to June 2014 in our hospital were collected. The patients were divided into two groups according to the random number table method, 73 cases in each. Patients in group A1 were given polyethylene glycol Interferon a-2a + ribavirin treatment, A2 group patients given conventional hepatoprotective therapy. The liver function indexes of 12 and 24 weeks after treatment in both groups were compared. Results After 12 weeks of treatment, the levels of TBIL, ALT, AST and HCV-RNA in both groups were not significantly different from those before treatment (all P> 0.05). After treatment for 24 weeks, the levels of TBIL, ALT, AST And HCV-RNA level was significantly better than A2 group, the difference was statistically significant (P <0.05). Conclusions Pegylated interferon alfa-2a plus ribavirin can significantly inhibit the replication of HCV in patients with hepatitis C cirrhosis. The liver function of patients can be obviously improved and the effect is obvious.